ReviewFrontiers in molecular biosciences2026
Emerging roles of Notch signaling in the tumor microenvironment of digestive system cancers.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploration and experimental verification of triaptosis-related prognostic genes and cells in gastric cancer.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Notch signaling pathway is an evolutionarily conserved cell-cell communication cascade with central roles in the development and progression of digestive system cancers. Beyond its established functions in tumor-cell proliferation and stemness, growing evidence indicates that Notch signaling also remodels the tumor microenvironment (TME). This review synthesizes the multifaceted roles of Notch signaling in the TME of digestive system malignancies. We discuss how aberrant Notch activity regulates the recruitment, polarization, and function of key tumor-infiltrating immune cells, including myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), regulatory T cells (Tregs), and dendritic cells (DCs), thereby fostering an immunosuppressive milieu. Notch signaling also drives the activation and sustained pro-tumorigenic activity of cancer-associated fibroblasts, promotes tumor angiogenesis, and contributes to extracellular matrix remodeling. Together, these effects establish a TME that supports digestive system cancer progression and therapy resistance. Given its central role in TME regulation, the Notch pathway represents a promising therapeutic target. We summarize current strategies, including Notch inhibitors and their combinations with immunotherapies, angiogenesis inhibitors, and other targeted therapies, that aim to overcome treatment resistance and improve clinical outcomes. A clearer understanding of Notch signaling in the TME will be essential for translating these insights into more effective therapies and improving prognosis in patients with digestive system cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.